Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms - NCT00844974-02114(Clinical Trial 272343)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Boston |
|
State:
|
|
MA |
| Zip Code: |
|
02114 |
| Conditions: |
|
Major Depression - Bipolar Disorder |
| Purpose: |
|
The purpose of this research study is to learn more about cognitive deficits in people with
certain mood disorders. The mood disorders are Major Depressive Disorder (MDD) and Bipolar
disorder, depressed type.
Cognitive deficits are problems with things like thinking and memory. People with cognitive
deficits may have problems concentrating and paying attention. When talking, they may have
trouble recalling a word they want to say. They may think slowly and have problems
remembering things. These deficits can affect an individual's ability to work and function
socially. Cognitive deficits that occur with depression may increase the risk of a relapse
of major depressive disorder.
We want to study the course of cognitive impairment in subjects as they are receiving
treatment for their depression. We want to find out if their cognitive deficits get better,
worse, or stay the same.
We also want to learn more about a stress hormone called cortisol that is produced in the
body. We want to study the relationship between cortisol and cognitive impairment. Recent
research has shown that cognitive impairment may be more severe in people who have high
levels of cortisol in their blood.
We will also measure the levels of a protein in your blood called brain-derived neurotrophic
factor (BDNF). BDNF helps the growth of new brain cells. It appears that the growth of new
brain cells lessens when people are depressed. Treatment with antidepressant medications
may cause BDNF levels to increase and return to normal. We are interested in studying the
relationship between BDNF levels and cognitive impairment throughout treatment.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
1. Eligible subjects will be inpatients admitted to the Massachusetts General
Psychiatric inpatient service, Blake 11 with diagnoses of MDD with and without
psychotic features and BPDD with and without psychotic features.
2. Subjects will include men and women aged 18-85.
3. Competent to give informed consent.
Exclusion Criteria:
1. Patients with illnesses that impair cognitive functioning including: vascular
dementia, and neurological illnesses including Parkinson's Disease, Huntington's
Disease, multiple sclerosis, and Alzheimer's Disease.
2. The following DSM-IV diagnoses: schizophrenia, schizoaffective disorder, delusional
disorder, organic mental disorder, substance use disorders including alcohol, active
within the past 6 months, acute bereavement, and psychotic disorder not elsewhere
classified.
3. Pregnant women |
|
|
|
| Study is available at: |
|
Massachusetts General Hospital
Boston, MA 02114
United States
Primary Contact:
John D. Matthews, MD
Email: jmatthews@partners.org
Phone: 617-724-9144 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 23, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|